Reviva to Participate in Upcoming Investor Conferences in May 2025

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for CNS, inflammatory and cardiometabolic diseases, has announced its participation in two upcoming investor conferences in May 2025.

CEO Laxminarayan Bhat will attend the Benchmark Healthcare House Call Virtual Investor Conference for a fireside chat and 1x1 meetings on May 29 at 11:15 a.m. ET, and the Lytham Partners Spring 2025 Investor Conference for a company presentation and 1x1 meetings on the same day at 2:00 p.m. ET. Both events will be held virtually.

News Market Reaction – RVPH

+16.85%

1 alert

+16.85% News Effect

On the day this news was published, RVPH gained 16.85%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CUPERTINO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following upcoming investor conferences.

Benchmark Healthcare House Call Virtual Investor Conference
Format: Fireside chat and 1x1 investor meetings
Date: Thursday, May 29, 2025
Time: 11:15 a.m. ET
Location: Virtual

Lytham Partners Spring 2025 Investor Conference
Format: Company presentation and 1x1 investor meetings
Date: Thursday, May 29, 2025
Time: 2:00 p.m. ET
Location: Virtual
Webcast Link: Click Here
To arrange a meeting with management please register for the event Here

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

What investor conferences will RVPH attend in May 2025?

RVPH will participate in two virtual conferences on May 29, 2025: the Benchmark Healthcare House Call Virtual Investor Conference at 11:15 a.m. ET and the Lytham Partners Spring 2025 Investor Conference at 2:00 p.m. ET.

Who will represent Reviva Pharmaceuticals at the May 2025 investor conferences?

Dr. Laxminarayan Bhat, Founder, President, and CEO of Reviva Pharmaceuticals, will represent the company at both conferences.

What is Reviva Pharmaceuticals' (RVPH) main business focus?

Reviva is a late-stage pharmaceutical company developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

What types of sessions will RVPH participate in during these conferences?

RVPH will participate in a fireside chat and 1x1 investor meetings at the Benchmark conference, and a company presentation and 1x1 investor meetings at the Lytham Partners conference.